logo
Plus   Neg
Share
Email

Myriad Genetics Withdraws FY20 Outlook Amid COVID-19 - Quick Facts

Myriad Genetics, Inc. (MYGN) announced Wednesday that due to the impact of the global coronavirus (COVID-19) pandemic, the company is withdrawing its financial guidance for the full year 2020.

In response to the pandemic, Myriad has made several changes to its business practices to promote the safety of both customers and employees. These include ceasing in-office sales calls and implementing virtual selling, granting all non-essential personnel the ability to work from home, enabling direct sample collection for patients and implementing policies to improve laboratory personnel safety.

While the uncertain timeframe of the Coronavirus pandemic makes it difficult to predict future business trends for the company, it will provide an update on its business, including the impact of COVID-19, on its next quarterly earnings call.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
The European Commission said Friday that it has signed a deal with Sanofi and GlaxoSmithKline to secure up to 300 million doses of their potential COVID-19 vaccine. Acella Pharmaceuticals recalled certain lots of hypothyroidism medication NP Thyroid in the form of tablets due to super potency, the U.S. Food and Drug Administration said in a statement. The company is recalling one lot of 15mg and one lot of 120mg of NP Thyroid that are packaged in 100 count bottles in strengths of 15 mg, and 120 mg, with expiration dates between October 2020 and November 2020. Walmart announced its decision to raise wages for around 165,000 hourly associates across all its U.S. stores starting October, and introduce a team-based operating model in Supercenters. In a tweet, the retail giant said, "Today we're introducing new leadership roles and cross-training opportunities, giving our associates more ways to grow their careers."
Follow RTT